Sophia Genetics (FRA:90B) Interest Expense: €-4.77 Mil (TTM As of Mar. 2026)


FRA:90B Sophia Genetics SA FRA:90B
72 GF Score
Price €4.98
GF Value €4.15
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sophia Genetics Interest Expense?

Sophia Genetics FRA:90B +4.18% 72 Interest Expense is €-4.77 Mil as of Mar. 2026. GuruFocus rates FRA:90B with a GF Score™ of 72/100 and a GF Value™ of €4.15 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sophia Genetics's interest expense for the three months ended in Mar. 2026 was € -1.44 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.77 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sophia Genetics's Operating Income for the three months ended in Mar. 2026 was € -14.95 Mil. Sophia Genetics's Interest Expense for the three months ended in Mar. 2026 was € -1.44 Mil. Sophia Genetics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sophia Genetics  (FRA:90B) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sophia Genetics's Interest Expense for the three months ended in Mar. 2026 was €-1.44 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-14.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €51.65 Mil.

Sophia Genetics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Sophia Genetics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Sophia Genetics Interest Expense Historical Data

* Premium members only.

The historical data trend for Sophia Genetics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sophia Genetics Interest Expense Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.58 -0.60 -0.54 -1.83 -3.89

Sophia Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.49 -1.42 -1.43 -1.44
FRA:90B
72GF Score
Sophia Genetics SA FRA:90B
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sophia Genetics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-4.77 Mil mean?
Sophia Genetics (FRA:90B) has a Interest Expense of €-4.77 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sophia Genetics and its competitors.
Is Sophia Genetics' Interest Expense too high?
Sophia Genetics' current Interest Expense is €-4.77 Mil. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Interest Expense compare to WEAV and NRC?
Sophia Genetics' Interest Expense of €-4.77 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Healthcare Providers & Services company?
A good Interest Expense depends on the Healthcare Providers & Services industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Sophia Genetics and its competitors. Sophia Genetics's current Interest Expense is €-4.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (FRA:90B) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.15, compared to a current price of €4.98 — trading 20% above its estimated fair value. The current Interest Expense is €-4.77 Mil. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Sophia Genetics (FRA:90B), the current Interest Expense is €-4.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sophia Genetics (FRA:90B) Overvalued in 2026?

Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued. The current stock price of €4.98 is trading 20% above its estimated GF Value™ of €4.15. GuruFocus considers Sophia Genetics to be Modestly Overvalued.

Key valuation signals for FRA:90B:

  • Interest Expense: €-4.77 Mil
  • GF Value™: €4.15 vs. price of €4.98 (20% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the FRA:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sophia Genetics Business Description

Other Exchanges SOPH:USA90B:Germany
Address La Piece 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score

Get the complete analysis for FRA:90B

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.98
Price
€4.15
GF Value